II. Overview of investigator responsibilities. FDA Guidance for Industry.
In conducting clinical investigations of drugs, including biological products, under 21 CFR part 312 and of medical devices under 21 CFR part 812, the investigator is responsible for:
- Ensuring that a clinical investigation is conducted according to the signed investigator statement for clinical investigations of drugs, including biological products, or agreement for clinical investigations of medical devices, the investigational plan, and applicable regulations
- Protecting the rights, safety, and welfare of subjects under the investigator’s care
- Controlling drugs, biological products, and devices under investigation (21 CFR 312.60, 21 CFR 812.100).
As a reminder, some investigators may be responsible for submitting certain clinical trial information to the National Institutes of Health clinical trials data bank under 42 U.S.C 282(j), 402(j) of the Public Health Service Act. Although not all investigators will be expected to meet this requirement, go to www.clinicaltrials.gov for further information about potential responsibilities.
Although specific investigator responsibilities in drug and biologics clinical trials are not identical to the investigator responsibilities in medical device clinical trials, the general responsibilities are essentially the same. This guidance discusses the general investigator responsibilities that are applicable to clinical trials of drugs, biologics, and medical devices.
An investigator’s responsibilities in conducting clinical investigations of drugs or biologics are provided in 21 CFR Part 312. Many of these responsibilities are included in the required investigator’s signed statement, Form FDA-1572 (see Attachment A) (hereinafter referred to as 1572). Note that although the 1572 specifically incorporates most of the requirements directed at investigators in part 312, not all requirements are listed in the 1572. Investigators and sponsors should refer to 21 CFR Parts 11, 50, 54, 56, and 312 for a more comprehensive listing of FDA’s requirements for the conduct of drug and biologics studies (As a reminder, some investigators may be responsible for submitting certain clinical trial information to the National Institutes of Health clinical trials data bank under 42 U.S.C 282(j), 402(j) of the Public Health Service Act. Although not all investigators will be expected to meet this requirement, go to www.clinicaltrials.gov for further information about potential responsibilities).
An investigator’s responsibilities in conducting clinical investigations of a medical device are provided in 21 CFR Part 812, including the requirement that there be a signed agreement between the investigator and sponsor (see 21 CFR 812.43(c)(4) and 812.100). The medical device regulations do not require use of a specific form for an investigator’s statement; and there are additional requirements not listed above (see Attachment B). Investigators and sponsors should refer to 21 CFR Parts 11, 50, 54, 56, and 812 for a more comprehensive listing of FDA’s requirements for the conduct of device studies.
Nothing in this guidance is intended to conflict with recommendations for investigators contained in the International Conference on Harmonisation (ICH) guidance for industry, E6 Good Clinical Practice: Consolidated Guidance (Good Clinical Practice Guidance, Guidances, including ICH guidances, are available on the Agency’s Web page).
Issued by:
Center for Drug Evaluation and Research
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
17 – 19 April 2024SCDM (Society of Clinical Data Management)Poland
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
Közelgő klinikai vizsgálatok
-
Henan University of Traditional Chinese MedicinePeking University People's Hospital; The First Affiliated Hospital of Zhengzhou... és más munkatársakMég nincs toborzásBronchiális asztmaKína
-
Karolinska InstitutetMég nincs toborzásÚjraélesztési utasítások kritikus állapotú betegek számára
-
MemorialCare Health SystemMég nincs toborzásPreeclampsia | Szülés utáni preeclampsia | Preeclampsia súlyos | Preeclampsia enyhe
-
University of Alabama at BirminghamMég nincs toborzásPulmonális hipertónia | Bronchopulmonalis dysplasia
-
Peking University People's HospitalMég nincs toborzásUltrahang | Mély tanulás | Elülső talofibuláris szalagKína
-
Leiden University Medical CenterJacobijn Gussekloo, Prof. dr.; Simon P. Mooijaart, Prof. dr.ToborzásÖregedés | Extrém hosszú élettartam | Hosszú élet | Családi hosszú életHollandia
-
Tartu University HospitalEstonia Research CouncilToborzás1-es típusú cukorbetegségÉsztország
-
University Hospital Southampton NHS Foundation...Még nincs toborzás
-
Ankara City Hospital BilkentMég nincs toborzásRegionális anesztézia morbiditása | Felnőtt | Anesztézia injekció beadásának helye
-
GlaxoSmithKlineMég nincs toborzásLégúti szincitiális vírusfertőzésekEgyesült Államok, Spanyolország, Belgium, Hollandia
-
EdiGene Inc.The First Affiliated Hospital of Henan University of Science and Technology; Changping...ToborzásLupus erythematosus, szisztémásKína
-
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.Még nincs toborzás